Prednisone for Decompensated Congestive Heart Failure

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00369044
Recruitment Status : Suspended
First Posted : August 29, 2006
Last Update Posted : April 8, 2009
Information provided by:
Hebei Medical University

August 28, 2006
August 29, 2006
April 8, 2009
October 2006
Not Provided
Change from baseline in serum creatinine level, Patient and physician-assessed symptom scales at day 1, day 3, the end of week 1 and week 2
Same as current
Complete list of historical versions of study NCT00369044 on Archive Site
Daily urine volume, changes in body weight, serum electrolyte levels at the end of week 1, week 2, respectively, and overall safety profile
Same as current
Not Provided
Not Provided
Prednisone for Decompensated Congestive Heart Failure
Chronic Administration of Prednisone in Management of Patients With Decompensated Congestive Heart Failure
We designed this, randomized, double-blind, placebo-controlled trial to determine the clinical efficacy of chronic administration of prednisone on renal function and clinical status when added to standard care.
Studies showed that glucocorticoids could specifically dilate renal vessel, increase in GFR, and regulate synthesis and release of atrial natriuretic peptide (ANP), upregulate ANP receptors on vascular endothelial cells, leading to significant diuresis and natriuresis. Adding glucocorticoids to standard care may potentiate the diuretic and natriuretic effects of diuretics and improve renal function, thus improve the clinical outcomes.
Phase 2
Phase 3
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double
Primary Purpose: Treatment
Heart Failure, Congestive
Drug: prednisone
Not Provided
Liu C, Chen H, Zhou C, Ji Z, Liu G, Gao Y, Tian L, Yao L, Zheng Y, Zhao Q, Liu K. Potent potentiating diuretic effects of prednisone in congestive heart failure. J Cardiovasc Pharmacol. 2006 Oct;48(4):173-6.

*   Includes publications given by the data provider as well as publications identified by Identifier (NCT Number) in Medline.
Same as current
July 2008
Not Provided

Inclusion Criteria:

  • Hospitalized with primary diagnosis of CHF
  • Patients with normal cortical function
  • LVEF <40%
  • Significant fluid overload, defined as ≥ 2 of the following

    • Enlarged liver or ascites
    • Peripheral or sacral edema ( ≥ 2+)
    • Jugular venous distention ≥ 10 cm
    • Pulmonary rales, pleural effusion on chest x-ray or orthopnea

Exclusion Criteria:

  • Severe stenotic valvular disease
  • Serum creatinine > 4 mg/dl
  • Patient refusal
  • Any signs of infection or any condition that would contraindicate an glucocorticoids use
  • Poor controlled hypertension
  • Poor controlled diabetes mellitus
  • Active myocarditis
  • Malignancy or other terminal illness
Sexes Eligible for Study: All
18 Years to 90 Years   (Adult, Senior)
Contact information is only displayed when the study is recruiting subjects
Not Provided
Not Provided
Not Provided
Not Provided
Hebei Medical University
Not Provided
Principal Investigator: Kunshen Liu, MD The First Hospital of Hebei Medical University
Hebei Medical University
June 2007

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP